Global Diabetic Ketoacidosis Market - 2023-2030

Global Diabetic Ketoacidosis Market - 2023-2030

The global diabetic ketoacidosis market reached US$ 1.5 billion in 2022 and is expected to reach US$ 2.3 billion by 2030 growing with a CAGR of 5.8% during the forecast period 2023-2030.

The diabetic ketoacidosis (DKA) market trends show rising research owing to the rising technological advancements and research studies. Several insulin and other therapies are being launched for the treatment of diabetic ketoacidosis. Fluid replacement treatments are also utilized for management of diabetic ketoacidosis in pediatrics as well as adults.

Furthermore, rising treatment for diabetic ketoacidosis due to the rising availability of approved electrolyte replacement therapy and increase in the number of diabetic ketoacidosis cases in the market, and an increase in the research and development is driving up the diabetic ketoacidosis market size.

The market is experiencing a growth in demand for treatment from North America areas as a result of the rising advancements in this field. With significant competitors like Novo Nordisk A/S, Baxter Healthcare Corporation, B. Braun Medical Inc., and Merit Pharmaceutical actively operating in the market, the market will grow in upcoming time.

Dynamics

Growing Research and Development by the Researchers Drive the Growth of the Diabetic Ketoacidosis Market

Absolute or relative insulin deficiency, together with an increase in cortisol, glucagon, growth hormone, and adrenaline, are the usual causes of diabetic ketoacidosis. Due to the increased hepatic gluconeogenesis, lipolysis and glycogenolysis caused by this insulin shortage, severe hyperglycemia, ketoacidosis, and ketonuria result. Improvements in circulatory volume or tissue perfusion, a gradual decrease in serum glucose as well as osmolality, correction of electrolyte imbalance, and identification and quick treatment of co-morbid triggering factors are among the therapy objectives for patients with hyperglycemic crises.

Frequent patient monitoring with relation to the aforementioned objectives using laboratory and clinical measurements is necessary for DKA treatment to be successful. In the majority of cases, there are triggering causes, such as an underlying infection, a missed insulin dose, diabetes that was not previously known, surgical stress, etc.

Improved patient outcomes depend on early diagnosis and treatment. Fluid resuscitation, insulin administration to address hyperglycemia, correction of acidosis, correction of electrolyte imbalances, and therapy of underlying causes or precipitants are all included in the course of treatment. Patients who receive sufficient care have a very good prognosis.

Rising Prevalence of Diabetic Ketoacidosis may Help in the Growth of the Market

The most serious metabolic disturbance brought on by sustained insulin insufficiency, as in type 1 diabetes, is diabetic ketoacidosis. A life-threatening illness called diabetic ketoacidosis is frequently detected too late. It requires an early diagnosis to avoid its effects, primarily neurological. In the Liguria Region, compared to years before to the shutdown, a rise in the incidence of diabetic ketoacidosis in newly diagnosed children and adolescents has been observed.

In 2022, researchers from the National Institutes of Health discovered 3062 new cases of Type 1 Diabetes T1D (54.3% males, mean age 9.5 4.3 years old), of which 1347 (44%) developed DKA. We saw a considerable rise in the prevalence of DKA between the pre- and post-COVID-19 periods (37.5%-49.4%, p .0001). The percentage of instances with moderate (+5.4%) and serious (+3.4%) DKA dramatically rose.

This rise may have been brought on by the longer time it took for a diagnosis to be made after the lockdown's restrictions decreased access to medical services. It would be beneficial to have more knowledge on the dangers of ketoacidosis through community and medical awareness initiatives.

Complications Associated with the Diabetic Ketoacidosis Treatment will Hamper the Growth of the Market

Hypoglycemia, commonly referred to as low blood sugar, occurs when insulin permits sugar to enter cells, which lowers blood sugar levels. Low blood sugar can result from a decline in blood sugar that occurs too quickly. The potassium level can go too low, or develop hypokalemia, as a result of the fluids and insulin required to treat diabetic ketoacidosis. The heart, muscles, and nerves can all be impacted by low potassium levels.

As an element of the treatment for diabetic ketoacidosis, potassium along with other minerals are typically given together with fluid replacement to prevent this. A rapid change in blood sugar level can result in cerebral edema, a swelling of the brain. Children seem to experience this more frequently, particularly those who have just been diagnosed with diabetes.

Segment Analysis

The global diabetic ketoacidosis market is segmented based on type, treatment and end user.

Owing to High Utilization, the Insulin Therap from Treatment Segment Accounted for Approximately 45.4% of the Diabetic Ketoacidosis Market Share

The death rate for DKA has dramatically dropped to 1% with the introduction of insulin and antibiotics. The standard of therapy is continuous intravenous insulin infusion. An early bolus of 0.1 U/kg followed by an infusion of 0.1 U/kg/h was advised by previous therapy guidelines. A current prospective randomized trial showed that individuals receiving hourly insulin infusions at 0.14 U/kg/hr do not require a bolus.

If the patient already has an anion gap when the plasma glucose level reaches 200–250 mg/dl, dextrose-containing drinks should be started, and the insulin rate of infusion may need to be decreased. According to numerous studies, treating adult patients with simple, mild diabetic ketoacidosis with subcutaneous insulin lispro per hour in a non-intensive medical facility may be safe and more affordable than treating such patients with intravenous normal insulin in an intensive care setting.

Patients who have never used insulin should start on a multi-dose insulin regimen at a dosage of 0.5 to 0.8 U/kg/day. Before ceasing the insulin drip, blood sugar should be checked again and the full metabolic profile completed in order to prevent the return of ketoacidosis during the transition phase. Insulin infusion must continue for 2 hours following the commencement of subcutaneous insulin.

Geographical Penetration

North America Accounted for Approximately 39.2% of the Market Share in 2022, Owing to the Strong Presence of Major Players and Increasing Healthcare Infrastructure Investment

Due to the rising need for diabetic ketoacidosis treatment in healthcare, manufacturers in North America have chances of increasing their operations. There are many producers and suppliers in North America and owing to the quick economic growth of the region, industrial production has expanded, driving the demand of treatment for diabetic ketoacidosis.

Increasing expenditure on healthcare and rising research studies, advancement of technologies for treatment of infectious disease, and increase in pharmaceutical and biotechnology business establishment across the region are also contributing to the growth of diabetic ketoacidosis market share of this region.

It is also anticipated that the main healthcare organizations' and enterprises' collaborative research projects as well as new product development, which constantly seeks to improve available alternatives, will contribute to the expanding demand. Individuals are becoming more aware of various treatment such as insulin therapy for intravenous usage for management purposes, leading to the expansion of the market in this region. The above-mentioned factors further proves the dominance of North America on a global scale.

Competitive Landscape

The major global players in the diabetic ketoacidosis market include Novo Nordisk A/S, Baxter Healthcare Corporation, B. Braun Medical Inc., ICU Medical, Inc., Pfizer Inc., Merit Pharmaceutical, SteriCare Solutions, Soxa Formulations & Research(Pvt.) Ltd, BD and Fresenius Kabi USA among others.

COVID-19 Impact Analysis

Russia Ukraine Conflict Analysis

Due to the low prevalence as well as absence of major market participants in this region, it is predicted that the Russia-Ukraine conflict will not have a significant effect on the worldwide diabetic ketoacidosis market. The growth of the global diabetic ketoacidosis market, however, is anticipated to be relatively unaffected by the import and export of raw materials over the forecast period.

By Type
• Pediatric Diabetic Ketoacidosis
• Adult Diabetic Ketoacidosis

By Treatment
• Insulin Therapy
• Electrolyte Replacement
Potassium
Magnesium
Bicarbonate
Phosphate
• Fluid Replacement

By End User
• Hospitals
• Academic & Research Institutes
• Specialty Clinics

By Region
• North America
U.S.
Canada
Mexico
• Europe
Germany
U.K.
France
Spain
Italy
Rest of Europe
• South America
Brazil
Argentina
Rest of South America
• Asia-Pacific
China
India
Japan
Australia
Rest of Asia-Pacific
• Middle East and Africa

Key Developments
• On May 10, 2022, new research from a real-world study by Joseph Bledsoe, MD and his colleagues of Intermountain Medical Center, found that using balanced crystalloids like lactated Ringer instead of saline solution reduces the risk of major adverse kidney events (MAKEs). For intravenous isotonic crystalloid infusion, common options are balanced crystalloids and ordinary 0.9% saline solution. Both are inexpensive and generally accessible.
• On January 5, 2023, Spinnaker International LLC, BPGC Management LP, and R Investments now own the majority of Nurse Assist LLC, the company that produces medical water products under the Stericare Solutions name. With a concentration on USP sterile water and saline, prefilled flush syringes, and sterile saline wound flush and irrigation kits, Stericare is an independent specialist manufacturer of medical grade saline and water products.

Why Purchase the Report?
• To visualize the global diabetic ketoacidosis market segmentation based on type, treatment, end user and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of diabetic ketoacidosis market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.

The global diabetic ketoacidosis market report would provide approximately 53 tables, 54 figures and 195 Pages.

DMI Opinion:

The global diabetic ketoacidosis market is going to see moderate growth in upcoming years owing to rising usage of insulin therapy for diabetic ketoacidosis. Several researches are taking place worldwide for insulin therapy development. Numerous advances are taking place leading to the growth of market such as novel electrolyte replacement therapy. According to DMI the diabetic ketoacidosis market will see a decent growth with several novel therapies in the market.

Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies